โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 34 in last 7 days ๐ŸŽ Food: 1 in last 7 days ๐Ÿงธ Products: 0 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 5 hours ago โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 34 in last 7 days ๐ŸŽ Food: 1 in last 7 days ๐Ÿงธ Products: 0 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 5 hours ago
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฌ๐Ÿ‡ง
๐Ÿ’Š

Caprelsa

vandetanib
Thyroid Neoplasms
โœ… Authorised
โœ…
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.

โš ๏ธ Patient safety

No

โš ๏ธ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.